Risk for surgical complications after previous stereotactic body radiotherapy of the spine

Johannes Roesch¹*, John B.C. Cho², Daniel K. Fahim³, Peter C. Gerszten⁴, John C. Flickinger⁵, Inga S. Grills⁶, Maha Jawad⁶, Ronald Kersh⁷, Daniel Letourneau², Frederick Mantel⁸, Arjun Sahgal⁹, John H. Shin¹⁰, Brian Winey¹¹ and Matthias Guckenberger¹

Abstract

Object: Stereotactic body radiotherapy (SBRT) for vertebral metastases has emerged as a promising technique, offering high rates of symptom relief and local control combined with low risk of toxicity. Nonetheless, local failure or vertebral instability may occur after spine SBRT, generating the need for subsequent surgery in the irradiated region. This study evaluated whether there is an increased incidence of surgical complications in patients previously treated with SBRT at the index level.

Methods: Based upon a retrospective international database of 704 cases treated with SBRT for vertebral metastases, 30 patients treated at 6 different institutions were identified who underwent surgery in a region previously treated with SBRT.

Results: Thirty patients, median age 59 years (range 27–84 years) underwent SBRT for 32 vertebral metastases followed by surgery at the same vertebra. Median follow-up time from SBRT was 17 months. In 17 cases, conventional radiotherapy had been delivered prior to SBRT at a median dose of 30 Gy in median 10 fractions. SBRT was administered with a median prescription dose of 19.3 Gy (range 15–65 Gy) delivered in median 1 fraction (range 1–17) (median EQD2/10 = 44 Gy). The median time interval between SBRT and surgical salvage therapy was 6 months (range 1–39 months). Reasons for subsequent surgery were pain (n = 28), neurological deterioration (n = 15) or fracture of the vertebral body (n = 13). Open surgical decompression (n = 24) and/or stabilization (n = 18) were most frequently performed; Five patients (6 vertebrae) were treated without complications with vertebroplasty only. Increased fibrosis complicating the surgical procedure was explicitly stated in one surgical report. Two durotomies occurred which were closed during the operation, associated with a neurological deficit in one patient. Median blood loss was 500 ml, but five patients had a blood loss of more than 1 l during the procedure. Delayed wound healing was reported in two cases. One patient died within 30 days of the operation.

Conclusion: In this series of surgical interventions following spine SBRT, the overall complication rate was 19%, which appears comparable to primary surgery without previous SBRT. Prior spine SBRT does not appear to significantly increase the risk of intra- and post-surgical complications.

Keywords: Spine tumor, Stereotactic radiotherapy of the spine, Radiosurgery, SBRT, Spine surgery, Complications
Background
The skeleton is one of the most common sites of metastatic disease spread in cancer patients with approximately 300,000 cases per year in the United States [1, 2]. Depending on the type of cancer, bony metastases occur in up to 70% of patients [3]. Furthermore, the spine is the most common site of bony metastasis, with postmortem detection of vertebral metastases in 30 to 36% of patients who died from neoplastic disease [4–6].

Pain medication combined with conventional radiotherapy (RT) is the standard of care for symptomatic bone metastases. However, recent developments in RT treatment planning and delivery enabled dose escalation within one or few treatment sessions and thus stereotactic body radiation therapy (SBRT) has emerged as a promising treatment technique [7]. By offering high rates of symptom relief and local control combined with low rates of toxicity, its acceptance and use are increasing [8, 9]. Nonetheless, symptomatic local failure or spinal instability after spine SBRT may occur, generating the need for subsequent surgery in the irradiated region [10, 11].

Prior RT is known to cause tissue alterations which might lead to difficult surgical conditions and subsequently to an increased risk of surgical complications. On the contrary, single dose RT might also be used to confine surgical induced fibrosis, which is common practice in keloid surgery, but was also found beneficial to prevent peridural fibrosis [12]. Surgical risk profiles following SBRT have been described in case series for recurrent tumors inside the lung [13, 14]. Despite fibrotic changes within the irradiated area, no increased surgical toxicity due to previous SBRT was reported for these cases. This study was conducted to specifically evaluate whether there is an increased risk of intra- and post-surgical complications after spine SBRT compared to historical results of surgery without previous SBRT.

Methods
Based on a retrospective international database of 704 patients treated with SBRT for vertebral metastases at 7 centers, 30 patients were identified who underwent surgery in a region previously treated with SBRT. Data for 32 surgical procedures, their treatment characteristics and complications were available, covering a period from November 2006 to July 2013. All centers are members of the Elekta Spine Radiosurgery Research Consortium and ethics approval was obtained by all institutions.

For each case the original surgical report was evaluated regarding the localization, reason and type of surgery, as well as intraoperative complications such as increased tissue fibrosis or blood loss. Additionally, patient charts were screened for the following postoperative complications: delayed wound healing (surgical site infection and/or wound dehiscence), blood loss, spinal instability, increased neurological deficit, pain, pneumonia, deep vein thrombosis, pulmonary embolism, and death within 30 days after surgery.

For plotting and statistical analyzes Microsoft Excel 2016 and R Studio 0.999 were used and next to descriptive statistical figures, Shapiro Wilk-, Wilcoxon rank sum-, Chi-Square- and Fishers exact test were applied. To account for multiple testing p-values were adjusted according to the false discovery rate approach [15].

Results
Thirty patients with a median age of 59 years (range 27–84 years) underwent SBRT for 32 vertebral metastases followed by surgery in the same region. Metastases of breast cancer and kidney cancer accounted for more than half of the cases. Median follow-up was 17 months from date of SBRT and 8 months from date of surgery. SBRT as well as conventional RT was exclusively delivered with Linear accelerators by Elekta. Doses for conventional RT were prescribed to the 95%-isodose according to ICRU 50/62. In contrast SBRT doses were prescribed in-homogeneously to the PTV encompassing isodose with variable maximum doses according to center and treating physician. In 17 cases, conventional radiotherapy had been delivered prior to SBRT at a median dose of 30 Gy in median 10 fractions. SBRT was most frequently administered in a single fraction with a median prescription dose of 18.4 Gy (median EQD2/10 = 43.5 Gy). Fractionated SBRT used a median of three fractions and a total dose of median 24 Gy (median EQD2/10 = 44 Gy). Overall, the median prescribed physical and EQD2/10 doses were 19.3 Gy and 44 Gy, respectively. Split into two groups of primary SBRT and secondary SBRT, the latter with a history of conventional RT in the same region, no significant difference was seen according to patient characteristics, SBRT dose and fractionation or surgical features. For a detailed assembly of fractionation and dose schemes the reader is referred to Tables 1 and 2.

The median time between SBRT and surgical salvage therapy was 6 months (range 1–39 months). The most frequent reason for surgery was progressive pain (n = 28) followed by progressive neurological deterioration (n = 15), fracture of the vertebral body (n = 13) or in one case spondylolisthesis (see Fig. 1). Open surgical decompression (n = 24) and/or stabilization using pedicle screws and rod fixation (n = 18) were the most frequently performed surgical procedures. Vertebroplasty / balloon kyphoplasty was performed 11 times in 10 patients, 5 of which in a combined approach with decompression and placement of spinal instrumentation devices (see Fig. 2).
Due to different risks for vertebroplasty alone and more complex surgery the patient population was divided into two groups for risk analyzes.

Five patients were treated with vertebroplasty only and formed the low-risk group. One patient was treated with SBRT to T10 and T12 followed by simultaneous vertebroplasty at both sites 10 months later due to increased pain and progressive vertebral body compression demonstrated on imaging without complication. SBRT prescription doses in this subgroup ranged from 15 to 24 Gy with 20.5 Gy in median in 1–3 fractions (median EQD2/10 = 50 Gy). Two patients had conventional RT prior to SBRT (40 Gy in 20 fr. / 30 Gy in 10 fr.). Overall, none of these five patients suffered from any complication intra- or postoperatively except residual pain in two cases.

Twenty-five patients in the high-risk group received 26 surgical salvage treatments. SBRT was delivered to a median prescription dose of 18.4 Gy (15–65 Gy) in mostly one fraction (1–17 fractions). Fifteen patients had received conventional RT prior to SBRT: Eleven patients had received 30 Gy in 10 fractions, three patients had received 20 Gy in 5 fractions and one patient had received 35 Gy in 14 fractions. One patient was sequentially treated in the L4 region starting with conventional irradiation (30 Gy in 10 fractions) followed by SBRT (19.4 Gy single fraction, time interval of 11 months), surgical decompression (time interval of 5 months), SBRT (17.6 Gy single fraction, time interval of 2 months) and subsequent repeat surgical decompression (time interval 8 months) without complications.

Intraoperatively, increased fibrosis complicating the surgical procedure was explicitly stated in one out of 26 surgical reports leading to an unintentional durotomy without further complications in this particular case. A second patient with intraoperative durotomy experienced an increased neurological deficit and delayed wound healing after surgery. In both cases the durotomy was sufficiently repaired during the surgical procedure and no revision surgery was needed.

Information regarding blood loss during surgery was available for 18 interventions. The median blood loss for cases was 500 ml (range 5–2000 ml). Five patients experienced a blood loss of greater than 1 l during the procedure; in all five cases, an open decompressive surgery in combination with stabilization devices was performed. Two of these five patients had delayed wound healing, and one patient died shortly after surgery. Furthermore, four of these five patients had received prior conventional fractionated RT in addition to SBRT at the treated level. The finding of local complications occurring only in the group of patients with conventional RT in addition to SBRT was not statistically significant. No significant differences were seen in this subgroup of patients in terms of primary site of disease, SBRT prescription dose, and time interval between SBRT and subsequent surgery.

Postoperatively, seven complications occurred which are summarized in Table 3. Overall, two cases of delayed wound healing were observed. One of these cases also suffered from an increased postoperative neurological deficit as already described. There was no case of subsequent spinal instability after surgery. Residual pain in the surgical area was observed in eight patients. Three patients had documentation of systemic complications: one pneumonia, one urinary tract infection and deep vein thrombosis, and one patient died shortly after the procedure.

| Table 1 | Patient and disease characteristics |
|---------|-----------------------------------|
| Patient characteristics | N = 30 |
| Median age at Operation | 59y (27–84) |
| Gender | Females: 17 Males: 13 |
| Primary site | Number Percentage |
| Kidney | 10 33% |
| Breast | 7 23% |
| Prostate | 3 10% |
| Melanoma | 2 7% |
| NSCLC | 1 3% |
| Colorectal | 1 3% |
| Other | 6 20% |

| Table 2 | Available RT-characteristics of all SBRT, primary SBRT only, secondary SBRT only with a history of conventional RT in the same region and conventional RT prior to SBRT |
|---------|-----------------------------------|
| SBRT over all | Number of treatments Median prescription dose (range) |
| Primary SBRT | Number of treatments Median prescription dose (range) |
| Secondary SBRT | Number of treatments Median prescription dose (range) |
| Prior conventional RT | Number of treatments Median prescription dose (range) |
| Over all | 32 19.3 (15–65) 15 21.7 Gy (15.7–65 Gy) 17 18 Gy (15–24 Gy) 16 30 Gy (20–40 Gy) |
| 1 fraction | 25 18.4 Gy (15–24 Gy) 10 20.5 Gy (15.7–24 Gy) 15 18 Gy (15–20 Gy) 3 20 Gy in 5 fractions |
| 2 fractions | 3 24 Gy 2 24 Gy 1 24 Gy 11 30 Gy in 10 fractions |
| 3 fractions | 2 17.7 Gy (15–20,4 Gy) 1 20.4 Gy 1 15 Gy 1 35 Gy in 14 fractions |
| 5 fractions | 1 25 Gy 1 25 Gy 1 1 40 Gy in 20 fractions |
| 17 fractions | 1 65 Gy 1 65 Gy |
surgical procedure due to causes that could not be determined.

**Discussion**

This study evaluated the risks of in-field spine surgery subsequent to SBRT. It is well documented that the overall complication rate associated with palliative spinal surgery in oncological patients is high. Due to their malignant disease and often multiple local and systemic therapies, cancer patients frequently suffer from multiple risk factors for both local as well as systemic intraoperative and postoperative complications. In the current study, we observed an overall surgical complication rate of 19% for the high risk group. Despite heterogeneous definitions and grouping of complications among previously published reports, this risk does not appear to be increased compared to series of surgical complications in comparable patients who undergo surgery without prior SBRT [16–19]. Regarding systemic complications, our rates of pneumonia (4%) and deep vein thrombosis (4%) are also within the expected range. In this cohort, one patient died within 30 days following surgery (4%) and similar mortality rates ranging from 3% to 13% have been reported in several retrospective and prospective surgical series [16–18, 20–23].

Regarding local complications, general risk factors such as age, stress, diabetes, medication, drugs, nutritional status or extent and duration of surgery have been described [24]. Explicitly in spinal surgery, a preoperative neurological deficit resulting from close proximity of the tumor to neural structures is a factor further increasing the risk for surgical complications [25, 26]. In a large retrospective study including almost 1000 patients by Finkelstein et al., a preoperative neurological deficit contributed to a 19% increase in mortality and a 71% increase in the risk of postoperative wound infection [16]. With 15 procedures undertaken due to progressive neurological deficit, patients with this risk factor were overrepresented in our study. However, postoperative complications were equally distributed amongst both of the subgroups.

Fibrotic tissue alteration after RT and SBRT is a well-known phenomenon. Therefore, this alteration might lead to difficult surgical conditions and to an increased risk of surgical complications. Surgical risk profiles following SBRT have been described in case series for recurrent tumors inside the lung [13, 14]. Despite fibrotic change within the irradiated area, no increased surgical morbidity due to previous SBRT was reported in these series of lung surgery. Regarding the time interval between irradiation and subsequent surgery, fibrotic remodeling inside the lung caused by SBRT seems to take place up to 1 year until reaching its maximum [27].

The evidence for increased fibrosis after spine SBRT is limited. By using radiosurgical doses of 10 Gy and 20 Gy in a mouse model, the extent and severity of epidural fibrosis after irradiation was shown to be dose and time dependent [28]. In our series only one surgical report explicitly mentioned complicating surgical conditions due to fibrotic remodeling. Additional cases with increased fibrosis but not complicating the surgical procedure may be assumed, but were not stated. In this context, two cases of durotomy and intraoperative cerebrospinal fluid leakage were observed which corresponds to a crude rate of 6.3% in 32 surgical sites. Durotomy may be associated with increased perioperative morbidity and long-term neurological sequelae [29]. According to large single institution series accidental durotomy occurs in 3.6–7.6% in primary spine surgery but its incidence increases in lumbar location or patients with pre-
existing fibrosis, which is best validated for revision surgery [30–34]. For total en bloc spondylectomy, preoperative conventional RT was a dose and time dependent risk factor for durotomy [35]. The authors reported an increased complication rate above 40 Gy or after a time interval of 1 year between RT and surgery.

Intraoperative blood loss correlates with the extent of surgery, leads to increased stress of the cardiovascular system and might require blood transfusions. Furthermore, it is associated with an increased wound infection rate [36]. In general, blood loss exceeding 2000 ml is uncommon in spinal surgery [33]. In our patient cohort we observed a median blood loss of 500 ml (range 5–2000 ml). Five patients lost more than 1 l of blood during the operation. This large variability in blood loss is most likely explained by the variety of surgical interventions performed in our study ranging from percutaneous instrumental stabilization to wider tumor resections partly combined with stabilization. Shehadi et al. reported a median blood loss of 500 ml in anterior or posterior approach only, 1350 ml for the combined simultaneously, and 2500 ml for the combined staged approach [37]. Similarly, Quan et al. reported a mean blood loss of 718 ml for surgeries with both anterior and posterior approaches [21]. In the series reported by Demura et al., a median blood loss of 1560 ml was seen, but only one quarter of patients received palliative surgery. In the majority of patients en bloc spondylectomy or vast debulking was performed. Likewise, Wang et al. reported a median blood loss of 1500 ml during their interventions where the spinal cord was circumferentially decompressed by a posterolateral transpedicular approach [38].

Conventional RT is a known risk factor for postoperative wound healing complications, like wound dehiscence or infection, in different organ sites including the spine [26, 39, 40]. Several large retrospective series reported increased rates of surgical site infections of 12–40% in pre-irradiated tissue compared to only 1–15% without prior RT [21, 25, 41–44]. Another smaller series of 42 patients reported two wound breakdowns after revision surgery and one wound infection in pre-irradiated patients [45]. However, one must be aware of a possible negative selection bias and poor description of RT regarding dose and interval between surgery and RT within this retrospective data. On the contrary, some studies could not confirm this relationship. Shehadi et al. retrospectively and Wang et al. prospectively could not find an association between preoperative irradiation and postoperative wound infection [37, 38]. In the latter, 60% of 140 patients were irradiated before surgery with mostly 30 Gy in 10 fractions and an interval between RT and surgery of more than 30 days. Table 4 summarizes studies analyzing surgical complications after spine surgery.

Table 3 Systemic, local and overall complication rate for 26 surgical interventions (open surgical decompression and/or instrumental stabilization) at 25 sites in 25 patients with previous conventional RT and SBRT or SBRT only at the same level

| Overall (n = 26) | RT + SBRT (n = 15) | SBRT (n = 11) |
|-----------------|-------------------|--------------|
| **Systemic complications** |                   |              |
| Pneumonia / urinary tract infection | 4 (in 3 patients = 12%) | 1 (7%) | 3 (in 2 patients = 27%) |
| Deep vein thrombosis       | 1                  | 0            | 1            |
| Perioperative death (within 30 days) | 1                  | 1            | 0            |
| Local complications        |                    |              |
| Increased neurological deficit | 3 (in 2 patients = 8%) | 1             | 0            |
| Spinal instability         | 0                  | 0            | 0            |
| Delayed wound healing      | 2                  | 2            | 0            |
| Postoperative bleeding/Hematoma | 0              | 0            | 0            |
| **Overall complication rate** | 7 (in 5 patients = 19%) | 4 (in 3 patients = 17%) | 3 (in 2 patients = 27%) |
recommendations regarding the right point in time for surgery following RT range between an absolute minimum of one to 3 weeks [43, 46, 50]. However, such planning is not always possible in the situation of the need for urgent surgery.

The issue of wound complications in patients who underwent spine surgery for metastasis with a history of prior radiotherapy was studied by Keam et al. [51]. In their series of 165 patients 35 patients received hypofractionated RT with doses of 18–30 Gy in 1–5 fractions. The 6-month cumulative incidence of wound complications for conventional RT was 17% and for hypofractionated RT was 6%. There was no significant difference, but a tendency for higher doses per fraction being associated with lower wound complication rates.

In our setting of surgery after SBRT, we observed delayed wound healing in two cases, corresponding to a crude rate of 8%, which is in the range of large surgical spine series of 7–12% [16, 21, 25, 38]. Furthermore, local complications were only seen in patients with prior history of conventional RT in addition to stereotactic RT supporting the thesis of Keam et al. A possible explanation for lower risk after SBRT despite higher biologically effective radiation doses compared to conventional palliative radiotherapy may be given by a more conformal dose distribution reducing the affected tissue to a minimum.

The favorable outcome in our study might be explained by the high level of radiotherapy and neurosurgical experience and expertise of all participating centers. All institutions have a clinical and scientific focus on the multi-disciplinary treatment of vertebral metastases. Additionally, SBRT and salvage surgery were performed at the same institution in all cases: this guarantees the best access of the neurosurgeon to all the relevant information of the previous SBRT treatment which might be beneficial for patient selection and planning of the surgical procedure. Still, expected complications were seen in this study. Bearing this in mind our results may not be assignable to centers with less expertise.

The relative small number of highly selected cases and its retrospective type are major limitations of this study. Therefore, statistical analyzes are to be treated with caution. Heterogeneity and missing details of surgical procedures like blood loss reflects the data’s origin from a multicenter database. Furthermore, heterogeneous definitions of complications among different studies may impede an actual comparison.

Conclusion
Based on the results of this multi-institutional study, surgery in a specialized center appears to be a safe salvage option in case of symptomatic local tumor recurrence or spinal instability after spine SBRT. The rate of complications does not appear to be higher compared to series without prior SBRT or series with prior conventional radiotherapy.

### Table 4 Summary of trials with general and local complication rates after spine surgery with and without previous RT

| Study, year | Main type of surgery | Complications rate | Wound complications | Perioperative deaths = 30 days mortality |
|------------|----------------------|--------------------|---------------------|----------------------------------------|
|            |                      | Overall / number of patients | RT + S / number of patients | S alone / number of patients | Overall / number of surgeries | RT + S / number of surgeries | S alone / number of surgeries |                        |
| Demura, 2009 [41] | Debulking / stabilization | – | – | – | 7.1% / 113 | 31.8% / 22 | 1.1% / 91 | – |
| Ghogawala, 2001 [43] | Posterolateral decompression and stabilization | / 85 | – | – | – | 32% / 28 | 12% / 34 | – |
| Lau, 2013 [34] | – | 21.7% / 106 | 23.5% / 81 | 16% / 25 | 3.8% / 106 | – | – | 1 (0.9%) |
| Pascal, 1998 [25] | Post + ant. approach | 18.6% / 145 | – | – | 11% / 145 | 12% | 1% | 3 (2%) |
| Quan, 2011 [21] | Post + ant. approach | 26% / 118 | 42% / 19 | – | 6.8% / 118 | 15.8% / 19 | 5% / 99 | 9 (7.6%) |
| Shehadi, 2007 [37] | – | – | – | 39% / 87 | – | No significant difference | – |
| Sundaresan, 2002 [42] | Ant. Approach + post. stab. | 80 | 15% / 40 | 40% / 40 | 13.8% / 80 | 25% / 40 | 2.5% / 40 | 1 (1.3%) |
| Wang, 2004 [38] | Posterior approach | 14.3% / 140 | 84 | 56 | 11.4% / 140 | No significant difference | 6 (4.3%) |
| Wise, 1999 [26] | Post + ant. approach | 25% / 80 | 15.5% / 41 | 9.3% / 39 | 17.1% / 80 | – | – | 2 (2.3%) |
| Yokogawa, 2014 [35] | Total en bloc spondylectomy | 40% / 50 | 77.8% / 18 | 18.8% / 32 | 8% / 50 | 22.2% / 18 | 0% / 32 | – |
Abbreviations
RT: Radiation therapy; SBRT: Stereotactic body radiation therapy

Acknowledgements
We thank all centers of the Elekta Spine Radiosurgery Research Consortium.

Funding
This research was partially supported through a research grant from Elekta AB, Stockholm, Sweden, with all institutions serving as members of the Elekta Spine SBRT Research Consortium. The data, however, are intellectual property of the individual group members and their institutions.

Availability of data and materials
All data reported.

Authors’ contributions
Author contributions to the study and manuscript preparation include the following. Conception and design: MG. Acquisition of data: all authors. Analysis and interpretation of data: JR, MG. Drafting the article: JR. Critically revising the article: PG, BCJC, ISG, FM, AS. Reviewed final version of the manuscript and approved it for submission: all authors. Statistical analysis: MG, JR. Study supervision: MG.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. 2Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, Canada. 3Department of Neurosurgery, William Beaumont Hospital, Royal Oak, Michigan, USA. 4Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 5Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 6Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan, USA. 7Department of Radiation Oncology, Riverside Medical Center, Newport News, Virginia, USA. 8Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany. 9Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada. 10Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA. 11Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Received: 20 June 2017 Accepted: 5 September 2017
Published online: 11 September 2017

References
1. Mundy GR. Metastasis to bone causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:384–93.
2. Li S, Peng Y, Weinhalll ED, Blaes AH, Cetin K, Chia VM, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;4:87–93.
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:6243s–9s.
4. Ortiz Gómez JA. The incidence of vertebral body metastases. Int Orthop. 1995;19:309–11.
5. Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult, and the impostors. Spine. 1990;15:1–4.
6. Kakhi VRD, Anvari K, Sadeghi R, Mahmoudian A-S, Torabian-Kakhi M. Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 2013;16:666–9.
7. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning J, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012;13:395–402.
8. Pan H, Simpson DR, Mells UK, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer. 2011;117:4566–72.
9. Dahele M, Hatton M, Stotman B, Guckenberger M. Stereotactic body radiotherapy: a survey of contemporary practice in six selected European countries. Acta Oncol Stockholm. 2015;54:1237–41.
10. Cunha MV, Al-Omair A, Atenafu EG, Masucci GL, Letourneau D, Korol R, et al. Vertebral Compression Fracture (VCF) after spine Stereotactic Body Radiation Therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys. 2012;84:e343–9.
11. Sahgal A, Whyne CM, Ma L, Larson DA, Fehlings MG. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 2013;14:e310–20.
12. Gerszten PC, Moossy JJ, Ricklinger JC, Welch WC. Low-dose radiotherapy for the inhibition of peridural fibrosis after reperfusory nerve root decompression for postamputation myopathy syndrome. J Neurosurg. 2003;99:271–7.
13. Neri S, Takahashi Y, Terasi T, Hamasawa H, Tomi K, Katsukari N, et al. Surgical treatment of focal recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5:2003–7.
14. Chen F, Matsuo Y, Yoshizawa A, Sato T, Sakai H, Bandoo T, et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol. 2010;5:1999–2002.
15. Benjaminji Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289–300.
16. Finkelstein JA, Zaveri G, Way E, Widmar M, Kreider H, Chow E. A population-based study of surgery for spinal metastases. Survival rates and complications. J Bone Joint Surg Br. 2003;85:1045–50.
17. Jansson K-A, Baurer HCF. Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc. 2006;15:196–202.
18. Patil CG, Lad SP, Santarelli J, Boakye M. National inpatient complications and outcomes after surgery for spinal metastasis from 1993–2002. Cancer. 2007;110:625–30.
19. Teleria S, Caroli F, Rau L, Pompili A, Carosi MA, Di Santo M, et al. Spine surgery in patients with metastatic breast cancer: a retrospective analysis. World Neurosurg. 2016;90:133–46.
20. Gokaslan ZL, York JE, Welch GL, McCutcheon IE, Lang FF, Putnam JB, et al. Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg. 1998;89:599–609.
21. Quan GMT, Vital JM, Auroar N, Obeid I, Paluszkie J, Diiafo A, et al. Surgery improves pain, function and quality of life in patients with spinal metastases: a prospective study on 118 patients. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc. 2012;21:1970–8.
22. Klempa J, Samii H. Surgical results for spinal metastases. Acta Neurochir. 1999;140:57–67.
23. Hirabayashi H, Ebara S, Kinoshita T, Yuzawa Y, Nakamura I, Takahashi J, et al. Clinical outcome and survival after palliative surgery for spinal metastases: palliative surgery in spinal metastases. Cancer. 2003;97:876–84.
24. Goo S, DiPietro LA. Factors affecting wound healing. J Dent Res. 2010;89:219–20.
25. Pascal-Mousserd H, Brioc G, Pointtall V, Siméon F, Vital JM, Sénéga J. Complications of vertebral metastasis surgery. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc. 2011;20:1970–8.
26. Wise JJ, Fischgrund JS, Herkowitz HN, Montgomery D, Kurz LT. Complication, survival rates, and risk factors of surgery for metastatic disease of the spine. Spine. 1999;24:1943–51.
27. Binkley MS, Shager JB, Chaudhuri A, Popat R, Maxim PG, Shultz DB, et al. Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. Radiat Oncol Lond Engl. 2016;11:40.
28. Yokogawa N, Murakami H, Demura S, Kato S, Yoshikoa K, Yamamoto M, et al. Effects of radiation on spinal dura mater and surrounding tissue in mice. PLoS One. 2015;10:e0138806.
29. Goodkin R, Laska LL. Unintended “incidental” durotomy during surgery of the lumbar spine: medicolegal implications. Surg Neurol. 1995;43:4–14.
30. Khan MH, Rih J, Steele G, Davis R, Donaldson WF, Kang JD, et al. Postoperative management protocol for incidental dural tears during
degenerative lumbar spine surgery: a review of 3,183 consecutive degenerative lumbar cases. Spine. 2006;31:2609–13.
31. Guerin P, El Fegoun A, Obeid I, Gille O, Lelong L, Luc S, et al. Incidental durotomy during spine surgery: incidence, management and complications. A retrospective review. Injury. 2012;43:397–401.
32. Baker GA, Cicak AM, Bransford RJ, Bellabarba C, Konodou MA, Chapman JR, et al. Risk factors for unintended durotomy during spine surgery: a multivariate analysis. Spine J Off J North Am Spine Soc. 2012;12:121–6.
33. Street JT, Lenehan BJ, DiPaola CP, Boyd MD, Kwon BK, Paquette SJ, et al. Morbidity and mortality of major adult spinal surgery. A prospective cohort analysis of 942 consecutive patients. Spine J Off J North Am Spine Soc. 2012;12:32–34.
34. Lau D, Leach MR, Than KD, Ziewacz J, La Marca F, Park P. Independent predictors of complication following surgery for spinal metastasis. Eur Spine J. 2013;22:1402–7.
35. Yokogawa N, Murakami H, Demura S, Kato S, Yoshioka K, Hayashi H, et al. Perioperative complications of total en bloc spondylectomy: adverse effects of preoperative irradiation. PLoS One. 2014:e98797.
36. McPhee IB, Williams RP, Swanson CE. Factors influencing wound healing after surgery for metastatic disease of the spine. Spine. 1998;23:726–732.
37. Shehadi JA, Scibilla DM, Suk I, Suki D, Maldaun MVC, McCutcheon IE, et al. Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patients. Eur Spine J. 2007;16:1179–92.
38. Wang JC, Boland P, Mitra N, Yamada Y, Lis E, Stubblefield M, et al. Single-stage posterolateral transpedicular approach for resection of epidural metastatic spine tumors involving the vertebral body with circumferential reconstruction: results in 140 patients. Invited submission from the joint section meeting on disorders of the spine and peripheral nerves, March 2004. J Neurosurg Spine. 2004;1:287–98.
39. Chadwick MA, Vienet D, Pettitt E, Dixon AR, Roe AM. Short course preoperative radiotherapy is the single most important risk factor for perineal wound complications after abdominoperineal excision of the rectum. Color Dis. 2006;8:556–61.
40. Schwartz SR, Yueh B, Maynard C, Daley J, Henderson W, Khuri SF. Predictors of wound complications after laryngectomy: a study of over 2000 patients. Otolaryngol–Head Neck Surg Off J Am Acad Otolaryngol–Head Neck Surg. 2004;131:61–8.
41. Demura S, Kawahara N, Murakami H, Nambu K, Kato S, Yoshioka K, et al. Surgical site infection in spinal metastasis: risk factors and countermeasures. Spine. 2009;34:635–9.
42. Sundaresan N, Rothman A, Manhart K, Kelliher K. Surgery for solitary metastases of the spine: rationale and results of treatment. Spine. 2002;27:1802–6.
43. Ghogawala Z, Mansfield FL, Boeges LF. Spinal radiation before surgical decompression adversely affects outcomes of surgery for symptomatic metastatic spinal cord compression. Spine. 2001;26:818–24.
44. Fourney DR, Abi-Said D, Lang FF, McCutcheon IE, Gokaslan ZL. Use of pedicle screw fixation in the management of malignant spinal disease: experience in 100 consecutive procedures. J Neurosurg. 2001;94:25–37.
45. Cameron Hatrick N, Lucas JD, Timothy AR, Smith MA. The surgical treatment of metastatic disease of the spine. Radiother Oncol. 2002;56:335–9.
46. Tibbs MK. Wound healing following radiation therapy: a review. Radiother Oncol. 1997;42:99–106.
47. Mishra MV, Austin L, Parvizi J, Ramsey M, Showalter TN. Safety and efficacy of radiation therapy as secondary prophylaxis for heterotopic ossification of non-hip joints. J Med Imaging Radiat Oncol. 2011;55:333–6.
48. Kolbi O, Knelles D, Barthel T, Kraus U, Flentje M, Eulert J. Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. Int J Radiat Oncol Biol Phys. 1997;39:961–6.
49. O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–41.
50. Ishayek E, Yamada J, Bilsky M, Schmidt M, Shaffrey C, Gerszten P, et al. Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review. Int J Oncol. 2010;36:533–44.
51. Keam J, Bilsky MH, Laufer L, Shi W, Zhang Z, Tam M, et al. No association between excessive wound complications and preoperative high-dose, hypofractionated, image-guided radiation therapy for spine metastasis. J Neurosurg Spine. 2014;20:411–20.